February 7, 2014
Protease Inhibitors Make a First Splash
The first wave of new HCV drugs arrived in the form of two protease inhibitors, boceprevir (Victrelis) and telaprevir (Incivek), which were approved in the U.S. in 2011 for the treatment of HCV genotype 1. They have not yet been approved specifically for HIV-coinfected patients, however -- and Cox suggested that their day in the sun may be setting.
In clinical trials, boceprevir and telaprevir have both been shown to dramatically increase HCV treatment success rates in therapy-naive, HIV-coinfected patients. But they still must be taken with interferon, and both drugs have been found to exacerbate the adverse effects seen among patients taking interferon-based therapies. Between those sobering data and extensive drug-interaction concerns with HIV medications, "it's not easy to take these medications," Cox said.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|The Day the HIV Treatment Pendulum Stopped Swinging|
|This Week in HIV Research: Major HIV Transmission Results; Case of HIV Remission; Gene Therapy; and More|
|HPTN 052: No Partner Infections With Viral Suppression|
|Leading HIV Expert Live-Blogs From IAS 2015|
|HIV Treatment at High CD4 Counts Protects Against Both AIDS and Non-AIDS Events in the START Study: Overall and in Subgroup Analyses|
|HIV Antiretroviral Study Highlights From IAS 2015|